Atlas Bio

📍 London & Basel, Switzerland🗓 Founded 2024👥 1 employees💰 Last funded 2026
Biotechnology Research🌐 atlas.bio
Website LinkedIn
What if you could compare how different treatments might act in patients before deciding what to develop, license or expand? Atlas runs in silico clinical trials in immunology using its foundation AI model of human biology to predict and compare patient responses across treatments and indications, helping biopharma teams decide what to advance, acquire or expand. We start from a treatment’s mechanism of action and apply it to patient readouts from Atlas’s proprietary datasets. Our AI model predicts how these readouts change in each patient on treatment. Our scientists interpret those predictions and work with your team to turn them into clear, actionable recommendations. This gives biopharma teams new patient-level data to de-risk business-critical pipeline decisions and make them with greater confidence. We need only a mechanism of action. No access is required to your asset-specific clinical efficacy data, molecular structure or proprietary data. Atlas was founded in 2024 and is based in Basel and London.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2024
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
3
Investor activity2024–2026 · investors recorded per year
2024120262
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Atlas Bio?
Atlas Bio has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Atlas Bio last raise funding?
The most recent investment in Atlas Bio recorded on gritt.io was in 2026.
When was Atlas Bio founded?
Atlas Bio was founded in 2024.
What industry is Atlas Bio in?
Atlas Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Atlas Bio based?
Atlas Bio is headquartered in London & Basel, Switzerland.